List of bibliographic references
Number of relevant bibliographic references: 15.
| Ident. | Authors (with country if any) | Title |
|---|
| 000355 (2011) |
Cécile Bétry [France] ; Adeline Etiévant [France] ; Laura Lambás-Se As [France] ; Andrew C. Mccreary [Pays-Bas] ; Nasser Haddjeri [France] | In vivo effects of pardoprunox (SLV308), a partial D2/D3 receptor and 5‐HT1A receptor agonist, on rat dopamine and serotonin neuronal activity |
| 000500 (2010) |
Gilles Gavaudan [France] ; David Magalon [France] ; Julien Cohen [France] ; Christophe Lançon [France] ; Georges Léonetti [France] ; Anne-Laure Pélissier-Alicot [France] | Partial Agonist Therapy in Schizophrenia: Relevance to Diminished Criminal Responsibility |
| 000552 (2010) |
Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas] | Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease |
| 000620 (2009) |
David A. Price [États-Unis] ; Alex A. Martinez [États-Unis] ; Alexandre Seillier [États-Unis] ; Wouter Koek [États-Unis] ; Yolanda Acosta [États-Unis] ; Elizabeth Fernandez [États-Unis] ; Randy Strong [États-Unis] ; Beat Lutz [Allemagne] ; Giovanni Marsicano [France] ; James L. Roberts [États-Unis] ; Andrea Giuffrida [États-Unis] | WIN55,212‐2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model of Parkinson’s disease |
| 000B30 (2005) |
Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] | End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study |
| 000D36 (2002) |
Stéphane Schück ; Danièle Bentué-Ferrer ; Diane Kleinermans ; Jean-Michel Reymann ; Elisabeth Polard ; Jean-Marc Gandon [France] ; Hervé Allain | Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers |
| 000E64 (2001) |
Frédéric Dolle [France] ; Héric Valette [France] ; Françoise Hinnen [France] ; Françoise Vaufrey [France] ; Stéphane Demphel [France] ; Christine Coulon [France] ; Michéle Ottaviani [France] ; Michel Bottlaender [France] ; Christian Crouzel [France] | Synthesis and preliminary evaluation of a carbon‐11‐labelled agonist of the α7 nicotinic acetylcholine receptor |
| 001058 (2000) |
Jean-Louis Montastruc [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 001286 (1999) |
Jean Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 001378 (1999) |
Jean-Louis Montastruc [France] ; Marc Ziegler [France] ; Olivier Rascol [France] ; Muriel Malbezin [France] | A randomized, double‐blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease |
| 001951 (1995) |
Blandine Jardon [France] ; Nicole Bonaventure [France] | Different effects of dopamine and Piribedil (a dopamine D2 agonist) on frog monocular optokinetic nystagmus asymmetry |
| 001A74 (1994) |
A. Héron [France] ; D. Lekieffre [France] ; E. Le Peillet [France] ; F. Lasbennes [France] ; J. Seylaz [France] ; M. Plotkine [France] ; R. G. Boulu [France] | Effects of an A1 adenosine receptor agonist on the neurochemical, behavioral and histological consequences of ischemia |
| 001C82 (1992) |
Robert Emre [Suisse] ; U. K. Rinne [Finlande] ; A. Rascol [France] ; A. Lees [Royaume-Uni] ; Yves Agid [France] ; X. Lataste [Suisse] | Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease |
| 001C83 (1992) |
C. Corbe [France] ; F. Arnaud [France] ; Y. Brault [France] ; C. Janiak-Bolzinger [France] | Effect of a dopaminergic agonist, piribedil (Trivastal 50 mg LP), on visual and spatial integration in elderly subjects |
| 001C90 (1992) |
Catherine Belzung [Italie, France] ; Paola Carletti [Italie] ; Flavia Angelucci [Italie] ; Stefano Puglisi-Allegra [Italie] ; Simona Cabib [Italie] | Behavioral effects of RO 41‐9067: A novel D2 dopamine receptor agonist |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/Title.i -k "agonist"
HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/Title.i \
-Sk "agonist" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Checkpoint
|type= indexItem
|index= Title.i
|clé= agonist
}}
| This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024 |  |
